Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Marimed (MRMD) over the last 15 years, with Q3 2025 value amounting to $1.3 million.

  • Marimed's Change in Accured Expenses fell 2921.9% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 7356.22%. This contributed to the annual value of $1.8 million for FY2024, which is 19532.61% up from last year.
  • Marimed's Change in Accured Expenses amounted to $1.3 million in Q3 2025, which was down 2921.9% from -$281000.0 recorded in Q2 2025.
  • Marimed's 5-year Change in Accured Expenses high stood at $5.1 million for Q2 2021, and its period low was -$8.8 million during Q4 2021.
  • For the 5-year period, Marimed's Change in Accured Expenses averaged around $84368.4, with its median value being -$136000.0 (2024).
  • Within the past 5 years, the most significant YoY rise in Marimed's Change in Accured Expenses was 322354.97% (2021), while the steepest drop was 101160.37% (2021).
  • Quarter analysis of 5 years shows Marimed's Change in Accured Expenses stood at -$8.8 million in 2021, then soared by 96.72% to -$289000.0 in 2022, then plummeted by 491.0% to -$1.7 million in 2023, then skyrocketed by 39.58% to -$1.0 million in 2024, then surged by 225.58% to $1.3 million in 2025.
  • Its Change in Accured Expenses stands at $1.3 million for Q3 2025, versus -$281000.0 for Q2 2025 and $1.9 million for Q1 2025.